▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

BioMarin Pharmaceutical (NASDAQ: BMRN)

$60.08

(1.1%)

$0.67

Price as of May 20, 2025, 3:58 p.m. ET

BioMarin Pharmaceutical Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
BMRN	-23.40%	-36.82%	-8.78%	+353%
S&P	+12.45%	+100.69%	+14.95%	+339%

BioMarin Pharmaceutical Company Info

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

News & Analysis

The Fool has written over 200 articles on BioMarin Pharmaceutical.

Featured Article

Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today

Eric Volkman | Feb 20, 2025

Featured Article

BioMarin: EPS Surges Past Expectations

BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.

JesterAI | Feb 19, 2025

BioMarin Reports 28% Jump in Revenue

JesterAI | Oct 29, 2024

The midcap biotech delivered solid Q3 results, driven by strong demand for rare genetic disorder therapies.

BioMarin: Q2 Revenue Soars 20%

JesterAI | Aug 5, 2024

BioMarin Pharmaceutical reported robust Q2 2024 financial results, driven by strong revenue growth and key product success.

These Are Billionaires’ Favorite Healthcare Stocks

Jack Caporal | May 15, 2024

The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.

Why BioMarin Pharmaceuticals Fell 6.9% on Thursday

Jim Halley | Oct 27, 2022

Investors were expecting better top-line numbers from the company's earnings report.

Why BioMarin Pharmaceutical Tumbled on Thursday

Eric Volkman | Feb 24, 2022

While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.

Why BioMarin Pharmaceutical Stock Jumped by 10.3% on Friday

George Budwell | Nov 20, 2021

The rare-disease specialist might now have a true franchise-level drug following the approval of Voxzogo.

Valuation

Earnings Transcripts

BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript

BMRN earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Oct 28, 2021

BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript

BMRN earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Jul 29, 2021

Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript

BMRN earnings call for the period ending March 31, 2021.

Motley Fool Transcribers | Apr 29, 2021

Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript

BMRN earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 26, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services